On August 28, 2019 PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, reported that nationally and internationally renowned clinician and oncologist, Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center (Press release, PharmaCyte Biotech, AUG 28, 2019, View Source [SID1234539071]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Hidalgo, a leading physician-scientist who specializes in pancreatic cancer and drug development, was recently appointed Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. Previously, Dr. Hidalgo was a Professor of Medicine at the Harvard Medical School and the Chief of the Division of Hematology Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center.
Dr. Hidalgo commented, "With PharmaCyte proceeding with the GMP production of the clinical trial product for its LAPC trial, I am more excited than ever to be a part of PharmaCyte’s clinical trial team. I remain enthusiastic about being the PI for the trial. I am also optimistic about the potential that PharmaCyte’s treatment may hold for patients suffering from LAPC and possibly other types of solid cancerous tumors. For example, PharmaCyte’s therapy for cancers involving the pancreas, liver and breast may offer an effective way to specifically target those cancers with little to no side effects from the chemotherapy."